Claudia Lengerke

Hoppe Seyler Str. 3
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Journal: Bone marrow transplantation

Published: May 20, 2026

Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve.

Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve.

Journal: Rheumatology (Oxford, England)

Published: April 22, 2026

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Journal: Journal for immunotherapy of cancer

Published: April 20, 2026

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal: Journal of hematology & oncology

Published: April 06, 2026

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.

Journal: Neoplasia (New York, N.Y.)

Published: February 25, 2026

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.

Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.

Journal: Rheumatology (Oxford, England)

Published: August 19, 2025

Laminin receptor characterization in acute myeloid leukemia: integrin α7β1 defines leukemic cells with migratory potential.

Laminin receptor characterization in acute myeloid leukemia: integrin α7β1 defines leukemic cells with migratory potential.

Journal: Experimental hematology

Published: August 04, 2025

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 03, 2025

High-dose chemotherapy and transplantation of autologous CD34+ selected stem cells for progressive systemic sclerosis adjusted to cardiac and lung manifestation: An open-label, non-inferiority phase 2 trial.

High-dose chemotherapy and transplantation of autologous CD34+ selected stem cells for progressive systemic sclerosis adjusted to cardiac and lung manifestation: An open-label, non-inferiority phase 2 trial.

Journal: Joint bone spine

Published: July 30, 2025

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.

Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.

Journal: Blood advances

Published: July 29, 2025

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Journal: Blood advances

Published: July 29, 2025

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.

Journal: Blood advances

Published: July 29, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026